Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet.


Journal

Cytometry. Part B, Clinical cytometry
ISSN: 1552-4957
Titre abrégé: Cytometry B Clin Cytom
Pays: United States
ID NLM: 101235690

Informations de publication

Date de publication:
01 2023
Historique:
revised: 18 11 2021
received: 01 07 2021
accepted: 29 11 2021
pubmed: 12 12 2021
medline: 19 1 2023
entrez: 11 12 2021
Statut: ppublish

Résumé

Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.

Sections du résumé

BACKGROUND
Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures.
METHODS
Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group.
RESULTS
We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies.
CONCLUSIONS
These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.

Identifiants

pubmed: 34894176
doi: 10.1002/cyto.b.22046
pmc: PMC10078694
doi:

Substances chimiques

Fluorescent Dyes 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

15-26

Informations de copyright

© 2021 The Authors. Cytometry Part B: Clinical Cytometry published by Wiley Periodicals LLC on behalf of International Clinical Cytometry Society.

Références

J Immunol Methods. 2017 Mar;442:54-58
pubmed: 28041941
Cytometry B Clin Cytom. 2023 Jan;104(1):15-26
pubmed: 34894176
Eur J Clin Invest. 2007 Jun;37(6):435-53
pubmed: 17537151
Nat Protoc. 2006;1(3):1522-30
pubmed: 17406444
Cancer. 2010 May 15;116(10):2372-81
pubmed: 20209617
Blood. 2002 Dec 1;100(12):3887-96
pubmed: 12393641
Am J Clin Pathol. 2020 Mar 9;153(4):554-565
pubmed: 32011681
Cancer Res. 2017 Mar 15;77(6):1261-1270
pubmed: 28254862
Blood Adv. 2021 Apr 13;5(7):2040-2052
pubmed: 33847740
Cytometry A. 2016 Jan;89(1):22-9
pubmed: 26243673
Int J Lab Hematol. 2014 Apr;36(2):184-96
pubmed: 24118926
Oncotarget. 2017 Jul 5;8(43):73483-73500
pubmed: 29088721
Int J Clin Exp Pathol. 2012;5(3):224-30
pubmed: 22558477
J Natl Compr Canc Netw. 2008 Oct;6(9):935-41
pubmed: 18926102
Haematologica. 2017 Feb;102(2):320-326
pubmed: 27658438
Cytometry A. 2008 Sep;73(9):834-46
pubmed: 18629843
Blood Cancer J. 2013 Jan 11;3:e100
pubmed: 23310930
Leukemia. 2018 Apr;32(4):874-881
pubmed: 29089646
Leuk Res. 2008 Feb;32(2):215-24
pubmed: 17675229
Biochem Med (Zagreb). 2018 Jun 15;28(2):020704
pubmed: 29666557
Blood. 2008 Feb 1;111(3):1067-77
pubmed: 17971483
Am J Hematol. 2005 Jul;79(3):243-5
pubmed: 15981222
Haematologica. 2012 Jun;97(6):895-902
pubmed: 22271903
Ann Oncol. 2014 Sep;25(9):1691-1700
pubmed: 24675021
Blood. 2001 Aug 15;98(4):979-87
pubmed: 11493442
Leukemia. 2017 Oct;31(10):2094-2103
pubmed: 28104919
Cytometry B Clin Cytom. 2004 Jul;60(1):1-13
pubmed: 15221864
Nat Rev Immunol. 2016 Jul;16(7):449-62
pubmed: 27320317
Cytometry B Clin Cytom. 2005 May;65(1):1-5
pubmed: 15800882
Oncotarget. 2010 Nov;1(7):483-96
pubmed: 21317447
Blood. 2017 Jan 19;129(3):347-357
pubmed: 27903527
Haematologica. 2012 Aug;97(8):1209-17
pubmed: 22315489
Blood. 2003 Jul 1;102(1):394-403
pubmed: 12649150
Leukemia. 2012 Sep;26(9):1908-75
pubmed: 22552007
Leukemia. 2006 Jul;20(7):1221-30
pubmed: 16728986
Haematologica. 2017 Feb;102(2):308-319
pubmed: 27758818
Leukemia. 2012 Sep;26(9):1986-2010
pubmed: 22948490
Leukemia. 2013 Sep;27(9):1923-5
pubmed: 23493026
Ann Hematol Oncol. 2015;2(5):
pubmed: 26203464
Leukemia. 2013 Oct;27(10):1981-7
pubmed: 23765225
Blood. 2003 May 1;101(9):3386-90
pubmed: 12506028
Cytometry B Clin Cytom. 2009 Jan;76(1):27-36
pubmed: 18548614
Leukemia. 2016 Aug;30(8):1769-72
pubmed: 26922887
J Immunol Methods. 1981;47(1):25-30
pubmed: 7310138
Cytometry B Clin Cytom. 2018 Sep;94(5):627-636
pubmed: 30240162
IEEE Trans Biomed Eng. 2008 Mar;55(3):1155-62
pubmed: 18334408
Cytometry B Clin Cytom. 2021 Sep;100(5):574-589
pubmed: 33369070
Leukemia. 2017 Apr;31(4):788-797
pubmed: 28090091
Cytometry A. 2015 Jul;87(7):636-45
pubmed: 25573116
Blood Adv. 2017 Feb 14;1(6):407-416
pubmed: 29296956
Haematologica. 2015 Mar;100(3):315-23
pubmed: 25425683
Blood. 2015 Jun 4;125(23):3618-26
pubmed: 25852055
Cytometry B Clin Cytom. 2016 Jul;90(4):358-67
pubmed: 26517178
Int J Lab Hematol. 2015 May;37 Suppl 1:133-43
pubmed: 25976971
Leuk Res. 2008 Jan;32(1):5-17
pubmed: 17576013
Blood. 2017 Mar 16;129(11):1420-1427
pubmed: 28031180
Leuk Res. 2007 Jun;31(6):727-36
pubmed: 17257673
Cytometry B Clin Cytom. 2020 Sep;98(5):399-411
pubmed: 32543774
Cytometry B Clin Cytom. 2020 Mar;98(2):131-145
pubmed: 31917512
Cytometry B Clin Cytom. 2005 Mar;64(1):9-17
pubmed: 15668954
Cytometry B Clin Cytom. 2009 Jan;76(1):18-26
pubmed: 18942105
Cytometry B Clin Cytom. 2007 Sep;72(5):427-32
pubmed: 17266154
BMC Hematol. 2018 Mar 13;18:6
pubmed: 29564138

Auteurs

Vincent H J van der Velden (VHJ)

Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Frank Preijers (F)

Department of Laboratory Medicine - Laboratory for Hematology, Radboudumc, Nijmegen, The Netherlands.

Ulrika Johansson (U)

Laboratory Medicine, SI-HMDS, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.

Theresia M Westers (TM)

Department of Hematology, Amsterdam UMC, location VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.

Alan Dunlop (A)

Department of Haemato-Oncology, Royal Marsden Hospital, Sutton, Surrey, UK.

Anna Porwit (A)

Department of Clinical Sciences, Division of Oncology And Pathology, Faculty of Medicine, Lund University, Lund, Sweden.

Marie C Béné (MC)

Hematology Biology, Nantes University Hospital and CRCINA, Nantes, France.

Peter Valent (P)

Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.
Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.

Jeroen Te Marvelde (J)

Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Orianne Wagner-Ballon (O)

Department of Hematology and Immunology; and Université Paris-Est Créteil, Assistance Publique-Hôpitaux de Paris, University Hospital Henri Mondor, Inserm U955, Créteil, France.

Uta Oelschlaegel (U)

Department of Internal Medicine, University Hospital Carl-Gustav-Carus, Dresden, TU, Germany.

Leonie Saft (L)

Department of Clinical Pathology and Oncology, Karolinska University Hospital and Institute, Solna, Stockholm, Sweden.

Sharham Kordasti (S)

Comprehensive Cancer Centre, King's College London and Hematology Department, Guy's Hospital, London, UK.

Robin Ireland (R)

Comprehensive Cancer Centre, King's College London and Hematology Department, Guy's Hospital, London, UK.

Eline Cremers (E)

Department of Internal Medicine, Division of Hematology, Maastricht University Medical Center, AZ, Maastricht, The Netherlands.

Canan Alhan (C)

Department of Hematology, Amsterdam UMC, location VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.

Carolien Duetz (C)

Department of Hematology, Amsterdam UMC, location VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.

Willemijn Hobo (W)

Department of Laboratory Medicine - Laboratory for Hematology, Radboudumc, Nijmegen, The Netherlands.

Nicolas Chapuis (N)

Assistance Publique-Hôpitaux de Paris. Centre-Université de Paris, Cochin Hospital, Laboratory of Hematology and Université de Paris, Institut Cochin, INSERM U1016, CNRS UMR8104, Paris, France.

Michaela Fontenay (M)

Assistance Publique-Hôpitaux de Paris. Centre-Université de Paris, Cochin Hospital, Laboratory of Hematology and Université de Paris, Institut Cochin, INSERM U1016, CNRS UMR8104, Paris, France.

Peter Bettelheim (P)

Department of Internal Medicine, Ordensklinikum Linz Barmherzige Schwestern - Elisabethinen, Linz, Austria.

Lisa Eidenshink-Brodersen (L)

Hematologics Inc, Seattle, WA, USA.

Patricia Font (P)

Department of Hematology, Hospital General Universitario Gregorio Marañon-IiSGM, Madrid, Spain.

Michael R Loken (MR)

Hematologics Inc, Seattle, WA, USA.

Sergio Matarraz (S)

Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service, University of Salamanca, Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto Carlos III, Salamanca, Spain.

Kiyoyuki Ogata (K)

Metropolitan Research and Treatment Centre for Blood Disorders (MRTC Japan), Tokyo, Japan.

Alberto Orfao (A)

Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service, University of Salamanca, Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto Carlos III, Salamanca, Spain.

Katherina Psarra (K)

Immunology Histocompatibility Department, Evangelismos Hospital, Athens, Greece.

Dolores Subirá (D)

Flow Cytometry Unit. Department of Hematology, Hospital Universitario de Guadalajara, Guadalajara, Spain.

Denise A Wells (DA)

Hematologics Inc, Seattle, WA, USA.

Matteo G Della Porta (MG)

IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy & Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Kate Burbury (K)

Department of Haematology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia.

Frauke Bellos (F)

MLL Munich Leukemia Laboratory, Munich, Germany.

Elisabeth Weiß (E)

MLL Munich Leukemia Laboratory, Munich, Germany.

Wolfgang Kern (W)

MLL Munich Leukemia Laboratory, Munich, Germany.

Arjan van de Loosdrecht (A)

Department of Hematology, Amsterdam UMC, location VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH